ABSSSI Treatment Market Size in the 7MM is expected to grow with a significant CAGR by 2034, estimates DelveInsight | Melinta Therapeutics, LLC, Merck, Pfizer, Allergan, Paratek Pharmaceuticals, Cumberland Pharmaceuticals, Teva Pharmaceuticals

DelveInsight's "Acute Bacterial Skin and Skin Structure Infections Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Acute Bacterial Skin and Skin Structure Infections, historical and forecasted epidemiology as well as the Acute Bacterial Skin and Skin Structure Infections market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock key insights into the ABSSSI Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ ABSSSI Market Size- https://www.delveinsight.com/sample-request/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Acute Bacterial Skin and Skin Structure Infections Market Report
• The highest rate of MRSA hospitalization was among the elderly-360.8 MRSA stays per 100,000 patients over 65 years of age which was more than three times higher for any other age group, 114.7 stays for infants, 19.2 for 1- to 17-year-olds, 58.1 for 18- to 44-year-olds, and 111.5 for 45- to 64-year-olds per 100,000.
• As per secondary analysis, ABSSSI accounted for almost 870,000 hospital admissions in the United States in 2004 which represents an increase of almost 30% in the incidence of this diagnosis over a 4-year period.
• Among nearly 5 million adult ABSSSI hospital admission, with admissions increasing 17.3% from 2005-2011. ABSSSI patients were primarily male (50.8%), white (60.3%), mean age 55.7 years.
• According to DelveInsight's analysis, the incidence of ABSSSI Infection is higher in men than women.
• As per analysis, the microorganisms isolated most frequently from SSTIs were Staphylococcus aureus (29.2%), Pseudomonas aeruginosa (11.9%), E. coli (8.9%) and Enterococcus faecalis (7.4%).
• The leading Acute Bacterial Skin and Skin Structure Infections Companies such as Melinta Therapeutics, LLC, Merck, Pfizer, Allergan, Paratek Pharmaceuticals, Cumberland Pharmaceuticals, Teva Pharmaceuticals, and others.
• Promising Acute Bacterial Skin and Skin Structure Infections Therapies such as Contezolid acefosamil, Rifaquizinone (TNP-2092), and others.

Stay ahead in the competitive landscape of the ABSSSI Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ ABSSSI Treatment Market Size- https://www.delveinsight.com/sample-request/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Bacterial Skin and Skin Structure Infections Epidemiology Segmentation in the 7MM
• Total Incident Cases of ABSSSI community/hospital
• Acute Bacterial Skin and Skin Structure Infections Age-specific Incident Cases
• Acute Bacterial Skin and Skin Structure Infections Gender-specific Incident Cases
• Acute Bacterial Skin and Skin Structure Infections Pathogen-specific Incident Cases

Download the report to understand which factors are driving ABSSSI epidemiology trends @ ABSSSI Prevalence- https://www.delveinsight.com/sample-request/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

ABSSSI Marketed Drugs
• DALVANCE (dalbavancin) : ABBVIE /Durata Therapeutics
DALVANCE (dalbavancin), developed by Durata Therapeutics, represents a groundbreaking therapy addressing the root cause of ABSSSI. Approved by the FDA in May 2014, DALVANCE is an intravenous long-acting lipoglycopeptide antibiotic. Its mechanism of action involves targeting cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of lipid II, a key precursor in this process. Effective against a broad spectrum of Gram-positive bacteria, including MRSA and Streptococcus pyogenes, DALVANCE exhibits bactericidal activity.

• ORBACTIV: Melinta Therapeutics
ORBACTIV, a product of The Medicines Company (now part of Melinta Therapeutics), represents a significant breakthrough in ABSSSI treatment. FDA-approved, it offers a novel approach to combating Gram-positive bacterial infections by inhibiting bacterial cell wall synthesis, particularly through binding to the peptidoglycan precursor lipid II. With demonstrated efficacy against various Gram-positive pathogens, including MRSA, ORBACTIV stands out for its unique pharmacokinetic profile, enabling once-daily dosing. This convenience not only simplifies treatment regimens but also holds the potential to enhance patient compliance and improve clinical outcomes in ABSSSI management.

Emerging ABSSSI Drugs
• MRX-4: MicuRx
MRX-4 is an injectable new oxazolidinone antibacterial agent, for the treatment of multidrug-resistant (MDR) which exhibits potent activity against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and penicillin-resistant Streptococcus pneumoniae (PRSP). In September 2018, the US FDA granted qualified infectious disease product status (QIDP) and fast track designation to contezolid acefosamil for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Currenty, the drug is in Phase III of clinical development.

• ZEVTERA (ceftobiprole): Basilea Pharmaceutica
ZEVTERA, developed by Basilea Pharmaceutica, is an intravenous cephalosporin antibiotic with rapid bactericidal activity against a broad spectrum of bacteria, including MSSA, MRSA, and susceptible Pseudomonas spp. It is currently approved for the treatment of hospital-acquired pneumonia. In August 2019, positive topline results from the TARGET study were reported, followed by similarly favorable outcomes from the ERADICATE study in June 2022. Subsequently, in April 2024, the US FDA granted approval for the New Drug Application (NDA) of ceftobiprole. This approval encompasses treatment indications for Staphylococcus aureus bacteremia (SAB), including right-sided infective endocarditis, acute bacterial skin and skin structure infections (ABSSSI), as well as community-acquired bacterial pneumonia (CABP).

Discover the future of ABSSSI Treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ ABSSSI Market Drivers and Barriers- https://www.delveinsight.com/sample-request/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Bacterial Skin and Skin Structure Infections Treatment Market
ABSSSI treatment aims to alleviate symptoms, enhance quality of life, halt disease progression, and prevent recurrence. Initial management, per IDSA guidelines, often involves oral antibiotics effective against streptococci for typical cellulitis cases. However, the prevalence of MRSA has led to a reevaluation of treatment strategies. Major treatment options for mild cases of non-purulent infections include penicillin, amoxicillin, amoxicillin-clavulanate, dicloxacillin, cephalexin, and clindamycin.

Acute Bacterial Skin and Skin Structure Infections Drugs Market Landscape
The Acute Bacterial Skin and Skin Structure Infections drugs market for treatments targeting Acute Bacterial Skin and Skin Structure Infections (ABSSSI) is xperiencing notable growth, driven by the increasing incidence of these infections and the rising prevalence of antibiotic-resistant bacteria. Innovations in antibiotic therapies, including novel agents and combination therapies, are expanding treatment options and fueling market expansion.

Explore the dynamics of the ABSSSI Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ ABSSSI Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Acute Bacterial Skin and Skin Structure Infections Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Acute Bacterial Skin and Skin Structure Infections Companies- Melinta Therapeutics, LLC, Merck, Pfizer, Allergan, Paratek Pharmaceuticals, Cumberland Pharmaceuticals, Teva Pharmaceuticals, and others.
• Acute Bacterial Skin and Skin Structure Infections Therapies- Contezolid acefosamil, Rifaquizinone (TNP-2092), and others.
• Acute Bacterial Skin and Skin Structure Infections Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Acute Bacterial Skin and Skin Structure Infections Unmet Needs, KOL's views, Analyst's views, Acute Bacterial Skin and Skin Structure Infections Market Access and Reimbursement

Table of Content
1. Key Insights
2. Report Introduction
3. Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market Overview at a Glance
4. Epidemiology and Market Methodology
5. Executive Summary of ABSSSI
6. Key Event
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Therapies
12. ABSSSI: Seven Major Market Analysis
13. Key Opinion Leaders' Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. Bibliography
19. Acronyms and Abbreviations
20. Disclaimer
21. About DelveInsight

List of Top Selling Market Research Reports in 2025

Biopsy devices market- https://www.delveinsight.com/report-store/biopsy-devices-market
Diabetic wound market - https://www.delveinsight.com/report-store/diabetic-wounds-market
Joint reconstruction devices market- https://www.delveinsight.com/report-store/joint-reconstruction-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cystic fibrosis market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Heart failure market- https://www.delveinsight.com/report-store/congestive-heart-failure-market
NK Cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Positive airway pressure device market - https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Uterine fibroids market- https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-market
Attention deficit hyperactivity disorder adhd market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
Lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.